Storyboard

Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative

Shares of telehealth company Hims & Hers Health closed at a three-year high Monday after the company announced a weight-loss treatment starting at $199 a month that will compete with Novo Nordisk’s Wegovy and Ozempic and enter the weight-loss market amid a shortage of branded treatments.

Avatar - Forbes
Curated by
Forbes
    • Wegovy
    • Ozempic
    • Novo Nordisk
    • Diabetes
    • Eli Lilly
Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative
Continue to read
3 stories in this Storyboard
    Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative To Wegovy

    Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative To Wegovy

    This is a BETA experience. You may opt-out by clicking here 11 minutes ago Social Media Should Have Labels Similar To Tobacco Products, Surgeon General Says—Noting ‘Significant Harm’ For Teens 4 hours ago China’s Nuclear Weapon Stockpile Is Growing Faster Than Any Other Country, Report Says 6 hours …

    MORE FROM FORBES

Related articles

More stories from Wegovy